{"protocolSection": {"identificationModule": {"nctId": "NCT00940927", "orgStudyIdInfo": {"id": "93-41"}, "organization": {"fullName": "Nemours Children's Clinic", "class": "OTHER"}, "briefTitle": "Dose-response of Albuterol in Asthmatics", "officialTitle": "Exclusion of Asthmatics From Clinical Trials Due to the 15 Percent Rule"}, "statusModule": {"statusVerifiedDate": "2015-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "1993-07"}, "primaryCompletionDateStruct": {"date": "1994-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "1994-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-06-27", "studyFirstSubmitQcDate": "2009-05-28", "studyFirstPostDateStruct": {"date": "2009-07-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-02-03", "resultsFirstSubmitQcDate": "2009-05-28", "resultsFirstPostDateStruct": {"date": "2009-07-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-14", "lastUpdatePostDateStruct": {"date": "2015-05-05", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Kathryn Blake, Pharm.D.", "oldOrganization": "Nemours Children's Clinic"}, "leadSponsor": {"name": "Nemours Children's Clinic", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study was to determine the lung function response after increasing doses of albuterol (a bronchodilator) in children and adults with asthma.", "detailedDescription": "Inhaled short-acting b2-agonists (SABA) are the most potent bronchodilators used today to treat acute symptoms of asthma and albuterol, a partial b2-agonist, is the most frequently prescribed asthma medication in the US. Although universally used in for acute asthma symptoms, SABA have been associated with a significant degree of interpatient variability. Many studies have characterized the SABA dose to bronchodilator response relationship under controlled conditions. However, few studies have explored the magnitude and sources of bronchodilator response variability, and no studies have characterized the dose versus bronchodilator response relationship using population pharmacokinetic/pharmacodynamic (PPK/PD) modeling. In the present study, we characterized the relationship between inhaled doses of albuterol and bronchodilation in 81 children and adults with moderate to severe persistent asthma using a population pharmacodynamic approach. The purpose of this study was to obtain estimates of the pharmacodynamic parameters that characterize the dose-response curve, including maximal dose for bronchodilation, and to quantify and identify sources of interpatient pharmacodynamic variability."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Albuterol", "Forced expiratory volume in one second", "Dose at fifty percent of maximum effect", "Maximum effective dose", "Metered dose inhaler", "Nebulizer"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 81, "type": "ACTUAL"}}, "armsInterventionsModule": {"interventions": [{"type": "DRUG", "name": "albuterol", "description": "Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)", "otherNames": ["Proventil MDI", "Proventil solution for nebulization"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Effective Dose 50% (ED50)", "description": "ED50 is the cumulative dose of albuterol required to bring about 50% of maximum effect of albuterol", "timeFrame": "15 minutes after each dose"}, {"measure": "Effect Maximum (Emax)", "description": "Maximum percentage of predicted FEV1 effect", "timeFrame": "15 minutes after each dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Eligibility Criteria:\n\n* Well-defined history of physician diagnosed asthma\n* Any ethnic background\n* 8 to 65 years old\n* Baseline pre-bronchodilator FEV1 of 40% to 80% predicted for age, height, and gender\n* No oral corticosteroid use, emergency room visits, or hospitalizations within the previous 3 months\n* Nonsmokers or less than a 5 pack-year history with no smoking in the previous year\n* Normal physical exam and no confounding diseases were selected\n* Able to withhold inhaled short-acting b2-agonists or inhaled anticholinergic drugs for 8 hours, oral antihistamines for 5 days, theophylline for 24 hours, and cromolyn, nedocromil, and inhaled corticosteroids for 2 hours prior to the study.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "8 Years", "maximumAge": "65 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Kathryn V Blake, Pharm.D.", "affiliation": "Nemours Children's Clinic", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Nemours Children's Clinic", "city": "Jacksonville", "state": "Florida", "zip": "32207", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}]}, "referencesModule": {"references": [{"pmid": "18583517", "type": "RESULT", "citation": "Blake K, Madabushi R, Derendorf H, Lima J. Population pharmacodynamic model of bronchodilator response to inhaled albuterol in children and adults with asthma. Chest. 2008 Nov;134(5):981-989. doi: 10.1378/chest.07-2991. Epub 2008 Jun 26."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Participants had to withhold inhaled short-acting beta2 agonist or inhaled anticholinergic drugs for 8 h, oral antihistamines for 5 days, theophylline for 24 h, and cromolyn, nedocromil, and inhaled corticosteroids for 2 h prior to the study.", "recruitmentDetails": "Participants were recruited from our asthma research clinic database or newspaper advertisements. Participants were recruited from 07/1993 to 10/1994.", "groups": [{"id": "FG000", "title": "Albuterol", "description": "Increasing doses of albuterol by MDI and nebulizer solution"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "81"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "81"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Albuterol", "description": "Increasing doses of albuterol by MDI and nebulizer solution"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "81"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "31"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "48"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30.2", "spread": "17.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "45"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "36"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "81"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Effective Dose 50% (ED50)", "description": "ED50 is the cumulative dose of albuterol required to bring about 50% of maximum effect of albuterol", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "ug", "timeFrame": "15 minutes after each dose", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Increasing doses of albuterol by MDI and nebulizer solution"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "141"}]}]}]}, {"type": "PRIMARY", "title": "Effect Maximum (Emax)", "description": "Maximum percentage of predicted FEV1 effect", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of predicted", "timeFrame": "15 minutes after each dose", "groups": [{"id": "OG000", "title": "Albuterol", "description": "Increasing doses of albuterol by MDI and nebulizer solution"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "81"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24.0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Albuterol", "description": "Increasing doses of albuterol by MDI and nebulizer solution", "seriousNumAffected": 0, "seriousNumAtRisk": 81, "otherNumAffected": 0, "otherNumAtRisk": 81}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Kathryn Blake, Pharm.D.", "organization": "Nemours Children's Clinic", "email": "kblake@nemours.org", "phone": "904 858 3806"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthmatic", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000000420", "term": "Albuterol"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000015149", "term": "Tocolytic Agents"}, {"id": "D000012102", "term": "Reproductive Control Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M3767", "name": "Albuterol", "asFound": "CNI", "relevance": "HIGH"}, {"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M17869", "name": "Tocolytic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Repr", "name": "Reproductive Control Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}]}}, "hasResults": true}